IP Library Granted Patent US 11,447,513
Granted Patent B2
US 11,447,513 · App. 17/174,286 · Granted Sep 20, 2022

Purification process of ferric carboxymaltose

Inventors: Ravishanker Kovi (Monroe Township, NJ); Jayaraman Kannapan (Vadodara, IN); Hemant Mande (Vadodara, IN); Rajesh Patel (Vadodara, IN); Ritesh H Panchal (Dahod, IN); Varun L Zambare (Vadodara, IN)
Assignee: RK PHARMA INC.
C07F15/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,447,513
App. No.
17/174,286
Granted
Sep 20, 2022
Kind
B2
Abstract

The present application provides processes for the purification of ferric carboxymaltose, the process includes the steps of dissolving crude ferric carboxymaltose in a first solvent; charging the ferric carboxymaltose solution in a reaction vessel with a second solvent and precipitating therefrom a ferric carboxymaltose precipitate; and isolating pure ferric carboxymaltose from the ferric carboxymaltose precipitate.

Claims (18)

1. A process for the purification of ferric carboxymaltose, comprising:

a. dissolving crude ferric carboxymaltose in a first solvent; wherein the crude ferric carboxymaltose and first solvent solution has a concentration of 0.20 g/ml to 0.33 g/ml;

b. adding the ferric carboxymaltose solution obtained in step a to a reaction vessel that contains a second solvent and precipitating therefrom a ferric carboxymaltose precipitate; and

c. isolating pure ferric carboxymaltose from the ferric carboxymaltose precipitate.

2. A process for the preparation of crude ferric carboxymaltose comprising:

oxidizing aqueous solution of maltodextrin with sodium hypobromite, wherein concentration of aqueous solution of maltodextrin is 0.25 g/ml to 0.50 g/ml; and

reacting the oxidized maltodextrin further with a ferric source therewith providing the crude ferric carboxymaltose.

3. The process of claim 2 , wherein the ferric source comprises ferric chloride or ferric chloride hexahydrate, and wherein the step of reacting the oxidized maltodextrin with the ferric source comprises reacting the oxidized maltodextrin with an aqueous solution of ferric chloride or ferric chloride hexahydrate having a concentration of 0.4 g/ml to 0.6 g/ml, in the presence of sodium carbonate as a base.

4. The process of claim 1 , wherein the first or second solvent comprises an acidic solvent, an alcoholic solvent, a ketone solvent, or an organic solvent or a mixture thereof.

5. The process of claim 2 , wherein the crude ferric carboxymaltose is purified by

a) charging sodium chloride into the crude ferric carboxymaltose aqueous solution,

b) heating the reaction mixture to a temperature between 50° C. to 60° C.,

c) filtering the reaction mass and removing therefore undissolved particulate,

d) adding an alcoholic solvent to the filtrate and stirring for a sufficient amount of time at a temperature of between 5° C. to 30° C., therewith precipitating the ferric carboxymaltose precipitate, and

e) filtering, washing and drying the ferric carboxymaltose precipitate to yield pure ferric carboxymaltose.

6. The process of claim 1 , wherein the first solvent comprises an acid, an amide, a ketone, an alcohol or another organic solvent, or mixtures thereof.

7. The process of claim 1 , wherein the second solvent comprises an alcohol, a ketone, or mixtures thereof.

8. The process of claim 7 , wherein the second solvent comprises methanol, acetone or a mixture thereof.

Assignments (3)
SECURITY INTEREST Recorded May 8, 2024
From: RK PHARMA INC.
To: CITIBANK, N.A.
Reel/Frame 067343/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2022
From: RK PHARMA SOLUTIONS LLC
To: RK PHARMA INC
Reel/Frame 060263/0406 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2021
From: KOVI, RAVISHANKER; KANNAPPAN, JAYARAMAN; MANDE, HEMANT; PATEL, RAJESH; PATEL, RITESH H.; ZAMBARE, VARUN L.
To: RK PHARMA SOLUTIONS LLC
Reel/Frame 056864/0933 →
Priority Claims (1)
IN 202021006073 · Feb 12, 2020 · national
Continuity (1)
Related Publication 20210277041A1 · Sep 9, 2021
Cited By (1)
US 12,721,859